At ISTH 2019, this year held in Melbourne, thousands of the world’s leading experts on thrombosis, hemostasis and vascular biology come together to present the most recent advances, exchange the latest science and discuss the newest clinical applications designed to improve patient care. This annual event is highly valued by the entire medical community.
What’s of interest for us, as the specialists in cancer-associated thrombosis?
First of all, you can’t miss the Scientific and Standardization Committee session dedicated to Hemostasis & Malignancy, showcasing the latest projects and updates.
The session is taking place on Saturday 6th July, 14:30, and it is first chaired by Cihan Ay and Casey O’Connell for the clinical part, and by Christophe Dubois and Tzu-Fei Wang for the basic science part.
Marc Carrier will start off the session, which will be mostly about anticoagulation during cancer treatment: which is the role of DOACs and how they interact with the anti-cancer treatment of choice? Thrombocytopenia is also going to be taken into consideration, through an update of the MATTER study, brought by Avi Leader.
The basic science part will focus on mouse models, plasminogen activation, antiphospholipds and lymphoma.A Q&A session shall clarify any doubts left.
On Sunday 7th, the ISTH official programme will officially start – it’s also time for a great number of Oral Communications.
The Cancer-Associated Thrombosis: Biomarkers oral communications session is chaired by Marc Carrier. We recommend you not to miss the update on the HYPERCAN study, presented by Marina Marchetti (OC 30.3 Hemostatic Biomarkers and Prediction of Prognosis in Newly Diagnosed Patients with Gastrointestinal Metastatic Cancer: Results from the HYPERCAN Study).
The Biomarkers of Thrombosis and Haemostasis: Venous Thromboembolism oral communications session is held a little later. We are genuinely eager to hear “A Clinical-Genetic Risk Score to Predict Cancer-Associated Venous Thromboembolism: a Development and Validation Study in Two Independent Prospective Cohorts” (OC 15.5) by Andres Muñoz.
All Oral Communications and Abstracts are not embargoed anymore and can be found here.
Don’t forget to tweet us any other OC that you deem worthy commenting on! Use the hashtag #ICTHICISTH.
Sunday also features a very early-in-the-morning State of the Art session. Those who are not too familiar with CAT will find this session very useful: Alok Khorana and Ingrid Pabinger will chair this session, which aims to summarize the basics.
Our fellow Editorial Board Members Janusz Rak, Nicole Kuderer and Agnes Lee will help understand the definition of coagulome, oncogene and oncomir in cancer, how to stratify the risk and how to treat CAT.
On Monday 8th, the Oral Communication frenzy continues: it’s now time to explore the Cancer and Coagulation Mechanisms, session chaired by Janusz Rak, – who will tell us more of the whole session in an interview that you will get to see later on ICTHIC Magazine.
What about Satellite Symoposia? On Tuesday 9th Bayer hosts a and very clinical – Satellite Symposium, “Anticoagulation in active cancer patients: how NOACs changed clinical practice” that is held during the lunchbreak. This symposium features Lord Kakkar, Alok Khorana, Peter Verhamme and Jeffrey Weits as speakers. Since the introduction of DOACs in the market, the general overlook on active cancer patients changed together with the treatment options. How do we go from evidence (trial) to practice (clinical)? Hear it in the session.
ICTHIC Magazine hopes that ISTH 2019 will be a fruitful conference for everyone involved.